Description: Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Home Page: www.biofrontera.com
Hemmelrather Weg 201
Leverkusen,
51377
Germany
Phone:
49 214 87 63 2 0
Officers
| Name | Title |
|---|---|
| Mr. Ludwig M. Lutter | Member of the Exec. Board |
| Ms. Pilar de la Huerta | Chief Financial Officer |
| Pamela Keck | Head of Investor Relations |
| Mr. Alexander Richardson | Head of UK Sales Team |
| Dr. Matthias Naumann | Head of Sales & Marketing - Europe |
Exchange: XETRA
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 5.3545 |
| Price-to-Book MRQ: | 6.2266 |
| Price-to-Sales TTM: | 3.109 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 102 |